Bevacizumab and Vasoconstriction
N/A
18 Years
50 Years
18 Years
50 Years
Not Enrolling
Male
Hypertension, Cancer
Male
Hypertension, Cancer
Trial Information
Bevacizumab and Vasoconstriction
Inclusion Criteria:
- Male 18-50 years old
- normal results of glucose, lipids and creatinine
- informed consent
Exclusion Criteria:
- History of abuse of drugs or alcohol
- History of malignant disease
- First degree relatives with a history of cancer before the age of 50
- First degree relatives with a history of premature cardiovascular disease
- Current use of medication
- Clinical evidence of cardiac of pulmonary disease
- Hypertension ( systolic>140mmHg, diastolic >90mmHg)
- Diabetes mellitus
- smoking
- a history of thombosis or a family history of recurrent thrombosis
- abnormality on ECG
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio
Outcome Time Frame:
Infusion of bevacizumab during 6 minutes
Safety Issue:
No
Principal Investigator
Gerard Rongen, MD PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UMCN
Authority:
Netherlands: The Central Committee on Research Involving Human Subject (CCMO)
Study ID:
BVZ1
NCT ID:
NCT00929058
Start Date:
June 2009
Completion Date:
November 2009
Related Keywords:
- Hypertension
- Cancer
- Hypertension
Name | Location |
|---|
